Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-002 + Vismodegib in Multiple Basal Cell Carcinomas
NCT04416516Phase 2Completed
- Sponsor
- Ascend Biopharmaceuticals Ltd.
- Start
- Jul 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gusacitinib in basal cell carcinoma (BCC), sponsored by Ascend Biopharmaceuticals Ltd.. Started Jul 2020; status: completed.
02
Drugs
gusacitinib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04416516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416516.